The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | The safety and efficacy of isatuximab for R/R myeloma: insights from ICARIA-MM, IKEMA & CANDOR
In this video, Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the safety and efficacy of isatuximab for the treatment of relapsed/refractory (R/R) multiple myeloma based on data obtained from several trials, including the ICARIA-MM trial (NCT02990338), the IKEMA trial (NCT03275285), and the CANDOR trial (NCT03158688). Dr Richardson also comments on the importance of carefully interpreting data from cross-trial comparisons and further compares the mechanism of action of isatuximab versus daratumumab, further highlighting the importance of antibody therapies in myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
